SB-656933-AAA

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 1

A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

CompletedNCT00504439

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2007-06-04End: 2007-09-06Updated: 2017-08-03

Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone

CompletedNCT00551811

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2007-10-08End: 2008-07-22Updated: 2017-08-07